Article
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2022
Marmouset Vincent, Decroocq Justine, Garciaz Sylvain, Etienne Gabriel, Belhabri Amine, Bertoli Sarah, Gastaud Lauris, Simand Célestine, Chantepie Sylvain, Uzunov Madalina, Genthon Alexis, Berthon Céline, Chiche Edmond, Dumas Pierre-Yves, Vargaftig Jacques, Salmeron Géraldine, Lemasle Emilie, Tavernier Emmanuelle, Delage Jérémy, Loirat Marion, Morineau Nadine, Blanc-Durand Félix, Pautier Patricia, Vergé Véronique, Auger Nathalie, Thomas Myrtille, Stefani Laetitia, Lepelley Marion, Boyer Thomas, Thepot Sylvain, Gourin Marie-Pierre, Bourquard Pascal, Duchmann Matthieu, Morice Pierre-Marie, Michallet Mauricette, Adès Lionel, Fenaux Pierre, Récher Christian, Dombret Hervé, Pagès Arnaud, Marzac Christophe, Leary Alexandra, Micol Jean-Baptiste
Abstract excerpt
PURPOSE: To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi). EXPERIMENTAL DESIGN: In a French cancer center, we identified and described the profiles of 13 t-MN diagnosed among 37 patients with ovarian cancer referred to hematology consultation for cytopenia under PARPi. Next, we described these 13 t-MN post-PARPi among 37 t-MN post...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.